Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab

Journal of Alzheimer's Disease

Volumn 34, Issue 4, 2013, Pages 897-910

  Lachno, D Richard ^a   Evert, Barbara A ^b   Vanderstichele, Hugo ^c,d   Robertson, Michael ^b   DeMattos, Ronald B ^a   Konrad, Robert J ^a   Talbot, Jayne A ^a   Racke, Margaret M ^a   Dean, Robert A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Pharmaceutical Product Development   (United States)

^c INNOGENETICS   (Belgium)

^d Biomarkable   (Belgium)

Author keywords

Alzheimer's disease; amyloid peptide; assay validation; biomarker; cerebrospinal fluid; plasma; solanezumab

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; SOLANEZUMAB;

ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; HUMAN; HUMAN TISSUE; MEASUREMENT ACCURACY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; VALIDATION STUDY;

EID: 84874938556     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122317     Document Type: Article

References (24)

1. Siemers ER, Dean RA, Demattos R, May PC (2006) New pathways in drug discovery for Alzheimer's disease. Curr Neurol Neurosci Rep 6, 372-378. (Pubitemid 44445680)
2. Zetterberg H, Mattsson N, Blennow K, Olsson B (2010) Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer's Res Ther 2, 32-36.
3. Siemers E, DeMattos RB, May PC, Dean RA (2010) Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark Med 4, 81-89.
4. Cummings JL (2011) Biomarkers in Alzheimer's disease drug development. Alzheimer's Dement 7, e13-e44.
5. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M,Winblad B, Coley N, Vellas B, Oxford Task Force Group (2011) Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95, 579-593.
6. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105. (Pubitemid 30027637)
7. Irizarry MC (2004) Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234. (Pubitemid 46591884)
8. Lachno DR, Vanderstichele H, De Groote G, Kostanjevecki V, De Meyer G, Siemers ER,Willey MB, Bourdage JS, Konrad RJ, Dean RA (2009) The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma β-amyloid isoforms using the INNO-BIA plasma Aβ forms multiplex assay. J Nutr Health Aging 13, 220-225.
9. Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA (2011) Validation of ELISA methods for quantification of total tau and phosphorylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies. J Alzheimer's Dis 26, 531-541.
10. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, for the AAB-001 201/202 Investigators (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer Disease. Arch Neurol 69, 1002-1010.
11. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's Dement 8, 261-271.
12. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. Clin Neuropharmacol 30, 317-325. (Pubitemid 350307310)
13. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038.
14. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
15. Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H,Van Everbroeck B, Cras P, Martin JJ,Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSFbiomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, 1143-1159. (Pubitemid 351822410)
16. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385-393.
17. Center for Drug Evaluation and Research (CDER), U.S. Department of Health and Human Services, Food and Drug Administration (2001) Bioanalytical Method Validation, Guidance for Industry. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
18. US Food and Drug Administration, Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. ICH April 1996. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf
19. US Food and Drug Administration, 21CFR58. http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=58.45
20. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33, 67-73.
21. Uenaka K, Nakano M,Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER (2012) Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 35, 25-29.
22. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, HoltzmanDM(2001) Peripheral anti-Aβ antibody altersCNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98, 8850-8855. (Pubitemid 32678116)
23. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
24. Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA (2012) Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. J Alzheimer's Dis 32, 905-918.